AGP Executive Report
Last update: 9 hours agoAI in Prostate Care: A study comparing first- and second-generation Aquablation systems finds similar perioperative outcomes, with HYDROS showing a small difference in waterjet pass duration. Aging-Driven Medtech Demand (Taiwan): As Taiwan becomes “super-aged,” companies are pushing foot-health tools, wound-care consumables (including higher-strength IPA prep pads), and home-care beds with AI/cloud features. Rehab Staffing Shortage: Hiwin’s robotic walking training aims to extend therapist capacity by guiding early weight-bearing exercises. Hospital Operations & Heat Risk (UK): The RCP warns the NHS isn’t ready for hotter summers, citing ongoing corridor care and high daily numbers of patients treated in unsuitable spaces. Alzheimer’s Access: FDA clears an at-home starting dose for Leqembi (lecanemab), shifting initial treatment from infusion clinics to subcutaneous autoinjector use. Ebola Vaccine Push (UK): Oxford begins the first phase I trial of a Bundibugyo Ebola vaccine candidate. Care Delivery & Data: Kaiser nurses protest AI concerns as Kaiser CEO argues value-based care gains. Obesity Drug Safety: Pharmacists caution that the new Wegovy pill still requires proper assessment and safe-use guidance, not DIY decisions. Cancer Diagnostics: Research suggests an algorithm could help some cancer patients with suspected pulmonary embolism avoid CT scans. Healthcare Security: A US senator urges FCC scrutiny of China-made wearables over potential data access risks.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26669747-926667378-8e38c44403b4a8c12299980e24b687dfe25aec42-1920x1080-100x56.jpeg)
![<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24990778-912932933-69ad66ff9a88b963b53a43ee2436f89da07d52ad-1280x720-100x56.jpeg)
![<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics ]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/25274951-913950647-3fb71511f2e18296d13ef1b96c30b224c2355251-1280x720-100x56.png)
